Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $3.38, $0.58 better than the analyst estimate of $2.80. Revenue for the quarter came in at $691.1 million versus the consensus estimate of $682.62 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.